Arab Israeli Conflict
Middle East News
Hi Tech News
Mylan rejected Teva's $41 billion bid earlier this week.
Acquisition would create leading company with potential to transform global market for generics.
Teva sought stay of lower court ruling that favored developers of generic versions of its top selling multiple sclerosis drug.
Over the past two years, Teva lost $57b. of value, leaving it with a remaining market value of $19b. It owes about $35b.
By GLENN YAGO
Teva’s fall is tragic. But we should not learn the wrong lessons.
By JPOST EDITORIAL
While there was great rejoicing in this particular area of the world during Christmas 1917, Israel in general and Jerusalem in particular have less cause for rejoicing at Christmas 2017.
By GREER FAY CASHMAN
Author Etay Shilony looks at how the brash culture of the Jewish State works for start-ups – but not long-term expansion.
By MAX SCHINDLER
The Mega supermarket chain is the latter-day descendant of the old Histadrut labor federation-owned chain of groceries that once dominated the Israeli landscape.
Does Teva still count as an Israeli company or is it a multinational corporation
whose roots lie in Israel?
By LIAT COLLINS
Got a minute? Here's the week in review.
By JPOST.COM STAFF
Today's roundup of the stories you may have missed.
According to the Bloomberg news agency, more than a dozen present and former executives of leading generic companies have been sued.
By JERUSALEM POST STAFF
Teva has not received any reports of adverse events signaling a potential link or exposure to valsartan, the health regulator said.
Please insert a valid email address